The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stent

European Heart Journal. Quality of Care & Clinical Outcomes
Maik J GrundekenBernard Chevalier

Abstract

In the ABSORB II trial, comparing Absorb™ bioresorbable vascular scaffold with metallic XIENCE™ everolimus-eluting stent (EES), a difference was found in site-reported new or worsening angina using adverse event (AE) reporting. However, the clinical relevance of this site-reported angina is unclear. The aim of the present study was therefore to investigate the clinical relevance of site-reported angina by evaluating its relation with cardiac endpoints, cardiovascular resource utilization (including diagnostics and treatment), positive exercise stress tolerance tests (ETTs), and Seattle Angina Questionnaire (SAQ). Site-reported new or worsening angina was captured on cardiac AE forms. There was a wide variation in the total number of days with site-reported angina (overall interquartile range 35-279 days). Patients with site-reported angina showed higher rates of cardiovascular events [including the patient-oriented composite endpoint of all deaths, all myocardial infarctions (MI), or all revascularizations (21.1 vs. 4.2%, P < 0.0001), all MIs (2.3 vs. 0%, P = 0.03), and all revascularizations (21.1 vs. 0.7%, P < 0.0001)], cardiovascular resource utilization (including stress tests, anti-anginal medication, diagnostic angiograph...Continue Reading

Associated Clinical Trials

References

Apr 12, 1973·The New England Journal of Medicine·P B OlivaR G Pluss
Aug 16, 2008·The New England Journal of Medicine·William S WeintraubG B J Mancini
Dec 25, 2009·Circulation. Cardiovascular Quality and Outcomes·Suzanne V ArnoldPaul S Chan
Oct 17, 2013·JAMA : the Journal of the American Medical Association·Mouin S AbdallahUNKNOWN FREEDOM Trial Investigators
Nov 10, 2013·Journal of the American College of Cardiology·Melody ZayaC Noel Bairey Merz
Dec 25, 2013·European Heart Journal·Filippo CreaCathleen Noel Bairey Merz
Sep 4, 2014·Circulation. Cardiovascular Quality and Outcomes·Paul S ChanJohn A Spertus
Sep 25, 2014·Circulation. Cardiovascular Quality and Outcomes·Suzanne V ArnoldJohn A Spertus

❮ Previous
Next ❯

Citations

Apr 1, 2016·European Heart Journal. Quality of Care & Clinical Outcomes·John F Beltrame

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Related Papers

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
M P SosaBernard Chevalier
Giornale italiano di cardiologia : organo ufficiale della Federazione italiana di cardiologia : organo ufficiale della Società italiana di chirurgia cardiaca
Antonio Bartorelli
© 2022 Meta ULC. All rights reserved